PHVS Overview

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Wall Street analysts forecast PHVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHVS is41.00 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Pharvaris NV revenue for the last quarter amounts to -44.27M USD, increased 4.94

Pharvaris NV. EPS for the last quarter amounts to -48818053.00 USD, increased 26.36

Pharvaris NV (PHVS) has 129 emplpoyees as of May 31 2026.

Today PHVS has the market capitalization of 2.09B USD.